Adaptimmune Therapeutics (NASDAQ: ADAP) , a clinical-stage biotech, saw its shares spike by as much as 10% in early morning trading Monday. Although the stock has cooled off somewhat in afternoon trading, its shares were still up by a healthy 8% as of 12:52 p.m. EDT Monday.
Adaptimmune's stock appears to be moving northward today in response to Pfizer 's $2.26 billion buyout of oncology specialist Trillium Therapeutics . In short, investors are apparently on the hunt for the next buyout play in oncology.
Image source: Getty Images.
For further details see:
Why Adaptimmune Therapeutics Stock Is Spiking Today